靶向 AML 中的分化阻滞：基于细胞表面的 CRISPR 筛选带来的新希望。
Targeting differentiation blockade in AML: New hope from cell-surface-based CRISPR screens.
机构信息
Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Irell and Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
出版信息
Cell Stem Cell. 2021 Apr 1;28(4):585-587. doi: 10.1016/j.stem.2021.03.006.
Accumulation of undifferentiated myeloid progenitors is a hallmark of AML, and targeting differentiation blockade represents a promising therapeutic strategy for AML. In this issue of Cell Stem Cell, Wang et al. (2021) conducted surface antigen-guided CRISPR screening and identified ZFP36L2 as a myeloid leukemia differentiation regulator and new therapeutic target.
未分化髓系祖细胞的积累是 AML 的一个标志，针对分化阻断的靶向治疗代表了 AML 一种有前途的治疗策略。在本期《Cell Stem Cell》杂志上，Wang 等人（2021 年）进行了表面抗原指导的 CRISPR 筛选，并鉴定出 ZFP36L2 是一种髓系白血病分化调节因子和新的治疗靶点。
Zotero 插件